Darolutamide 300mg Tablets

Product Introduction

Darolutamide 300mg is an androgen-receptor inhibitor used for non-metastatic castration-resistant or metastatic hormone-sensitive prostate cancer. It is added to continuing testosterone-lowering treatment; some metastatic regimens also include docetaxel.

How to use

Take the tablets twice daily with food, swallowing them whole. The usual 600mg dose requires two 300mg tablets at each administration, although kidney or liver impairment and adverse effects can require a lower dose. Continue the accompanying androgen-deprivation treatment unless surgical castration has already been performed.

How it works

Darolutamide binds androgen receptors and blocks testosterone and related hormones from activating them. This inhibits hormone-driven gene signalling that supports prostate-cancer growth.

Side effects

Fatigue, pain in the limbs, rash and changes in liver enzymes or blood counts can occur. Ischaemic heart disease and seizures are uncommon but important risks. Chest pain, sudden weakness or a seizure requires emergency assessment.

Important information

Kidney and liver function influence dosing. Strong enzyme/transporter inducers can reduce exposure, while rosuvastatin and other BCRP/OATP substrates can have substantially increased levels. PSA, symptoms and imaging are followed together rather than using one result alone.